Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following divisions: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.

Fumapharm is a privately held pharmaceutical company.

Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland.

Edison is a world leader in the discovery and development of redox drugs. The company has obtained orphan designation in both the United States and Europe for its first drug candidate, EPI-743 . Vincerinone is now in phase 2 clinical development. It is being evaluated in multiple clinical indications where defects in the mitochondrial proteins and redox control have been well characterized.

The 301 Hospital (Chinese: 三〇一医院) or People's Liberation Army General Hospital (Chinese: 中国人民解放军总医院), which constitutes simultaneously the PLA Postgraduate Medical School (Chinese: 中国人民解放军医学院), located in Beijing, China, is a military hospital directly subsidiary to Logistic Support Department of the Central Military Commission and the largest general hospital under the auspices of the People's Liberation Army. Its mission includes assuring the health of PLA and China's leaders.

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

CSPC NBP Pharmaceutical Co. Ltd. manufactures and sells pharmaceutical products. The firm offers butylphthalide soft capsules and injections, and pharmaceutical raw materials. The company was founded on April 23, 2003 and is headquartered in Shijiazhuang, China.

Latvian Biomedical Research and Study centre (BMC) is the scientific institute in molecular biology and biomedicine in Latvia. Since its establishment in 1993 it has evolved into a scientific centre performing basic as well as applied research in molecular genetics, vaccine development, genomics and proteomics, cancer biology, immunology, biotechnology, stem cell biology, structure biology and other scientific areas.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Jiangsu Wangao Pharmaceutical Co., Ltd., established on 2003-11-28, Business scope includes production and sales of tablets,Powder,dry suspension,hard capsule,Granules,soft capsule,Pills,suppositories(Softgel only),Imported drug sub-packaging,small volume injection;drug development,technology transfer,consult;Health product development,technology transfer,consult;Chinese herbal medicine planting,buy,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Wuhan Children's Hospital is a Chinese private company located in Wuhan that engages in providing general medical and surgical services and other hospital services.

Wellstat Therapeutics Corporation is a privately-held biopharmaceutical company located in Gaithersburg, Maryland. Dedicated to the discovery, development and commercialization of innovative therapeutics that expand the frontiers of medicine, Wellstat Therapeutics Corporation is committed to improving the lives of patients with chronic and life-threatening diseases.\nWellstat Therapeutics's focus is in the following fields:\nOncology\nMetabolic Diseases\nNeurodegenerative Diseases\nNeurometabolic Diseases\nWellstat Therapeutics is developing an extensive and diverse pipeline of novel small molecule therapeutic agents. The Company owns a broad patent portfolio covering this technology and is constantly expanding its intellectual property estate. Wellstat Therapeutics' pipeline spans the stages of development from discovery through Phase III clinical trials.\nWellstat Therapeutics was founded in 1985. The Company has a highly talented management team with significant experience in drug discovery, development, and commercialization. Samuel J. Wohlstadter, a company founder and the Chief Executive Officer was also a founder of Amgen Inc., Applied Biosystems (currently a division of Applera Corporation), IGEN International Inc. (currently a subsidiary of Roche), BioVeris Corporation (currently a subsidiary of Roche), and Hyperion Catalysis International, Inc.\nWellstat Therapeutics employs dedicated scientists, business professionals and support personnel at its state-of-the-art facilities in Gaithersburg, Maryland. Wellstat Therapeutics is part of the Wellstat Group of Companies, one of the largest and leading bioscience employers in the Baltimore-Washington Metropolitan Area. The Wellstat Group of Companies has expertise in all stages of discovery research and development, including:\nChemistry\nCell and Molecular Biology\nDisease Models\nTranslational Biology\nClinical Research and Development\nProject Management\nRegulatory Quality Assurance and Control\nManufacturing\nLegal and Financial

BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA.

Shanghai Ruibo Biotechnology Co., Ltd., established on 2012-08-03, The scope of business includes engaging in biotechnology,Medical Technology,Ecotechnology,electronic technology,Environmental Technology,Technology development in the field of chemical science and technology,technology transfer,Technical Services,technical consulting,Class I medical device,Chemical products and raw materials(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),electronic product,Sales of laboratory equipment. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Avesthagen is a life science company pioneering the convergence between Food, Pharma and Population Genetics leading to Predictive Preventive Personalized Healthcare. The business model of Avesthagen is to combine IP & product development through in-house research and collaborations. Avesthagen has built and continues to build an integrated, systems biology approach of capabilities, products, infrastructure and technology that allows for and facilitates ‘cross talk’ between numerous disciplines, leading to unique and innovative solutions. They employ 450 people worldwide and are headquartered in Bangalore, India.

Tianjin Gudui Biomedical Technology Co., Ltd., established on 2010-08-26, Business scope includes biological(except narcotics)technology development,consult,Serve,transfer.(The country has a special,Franchised,Execute according to regulations.)

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

Jiangsu Ruibo Biotechnology Co., Ltd., established on 2016-05-31, The scope of business includes engaging in biotechnology,medical technology,Ecotechnology,electronic technology,Technology development in the field of chemical science and technology,technical consulting,Technical Services,technology transfer;medical instruments,Production of biological kits for diagnostics,Sales;Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),Supporting instruments and supplies for scientific research,electronic product,Laboratory Equipment Sales;Manage the export business of the company's self-produced products and the machinery and equipment needed by the company,spare parts,Raw and auxiliary materials and technology import business.(Except for commodities and technologies that are restricted by the state to be operated or imported and exported by enterprises)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)